信达生物玛仕度肽获批糖尿病适应证,如何与礼来及诺和诺德明星药竞争?

澎湃新闻
Sep 19

信达生物 视觉中国 资料图国产GLP-1创新药迎来新进展。9月19日,信达生物(1801.HK)宣布,玛仕度肽注射液第二项适应证获得国家药监局批准,用于成人2型糖尿病患者的血糖控制。这是继今年6月获批减重适应证后,该药的第二个获批适应证。至此,玛仕度肽已在减重和控糖两个主要代谢领域都已获批。据信达生物介绍,玛仕度肽是全球首个获批的GCG/GLP-1双受体激动剂,在GLP-1受体激动剂的基础上激动...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10